PRECISION BIOSCIENCES INC reports $25.1 million Q1 loss

PRECISION BIOSCIENCES INC [DTIL] has reported fiscal Q1 loss of $25.10 million.

On a per-share basis, the DE based company said its diluted earnings are $0.23.

The Biological Products, Except Diagnostic Substances firm posted revenue of $8.80 million in this period.

Also Read:

• Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023
• Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023
• Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting
• Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting